Iterative Health
The Corporate Development Associate will support the full M&A lifecycle, from sourcing and evaluating potential acquisitions through due diligence, transaction execution, and integration. Reporting to the VP of Corporate Development, the role works closely with the executive team and cross‑functional leaders to drive growth of the research site network.
Headquarters
Cambridge, Massachusetts, United States
Company Size
51-200 employees
Founded
2017
Iterative Health is a clinical research network company that empowers a global network of community-based research sites and sponsors to accelerate the development and delivery of novel therapies. It operates across GI, Hepatology, Obesity, and Cardiology, connecting sponsors and CROs with high-performing research sites to improve trial enrollment, site activation, and patient access. By combining clinical expertise, AI-powered tools, and operational support, Iterative Health helps bring life-changing therapies to market faster.
ECCO 2026 Data Validate Iterative Health’s Site Network Model for Faster, More Consistent Trial Execution
3 weeks ago
Iterative Health Adds Nadege Gunn as CMO, Hepatology and Obesity
1 month ago
Iterative Health Appoints Bill Kayser as President and Chief Financial Officer
Sep 30, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Iterative Health.
4% below the average for this role
Iterative Health Appoints Nadege Gunn, MD, as Chief Medical Officer, Hepatology and Obesity
1 month ago